Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Ustekinumab in TNF-inhibitor failure psoriatic arthritis
NCT04632927Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA) (2 arms), sponsored by Novartis. Primary endpoint: Health Assessment Questionnaire - Disability Index Response at 28 weeks. Started Dec 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04632927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632927.